CHEAPEST FDA Play with MASSIVE upside potential .stock is still under radar but this will change once they resubmit the NDA in this Quarter . MEGA Drug targeting a $3+ BILLION Market is close to NDA-Resubmission expected before year end with potential FDA approval in Q2 .Market cap of $21 million is a PURE GIFT , this low float stock could run to $4+ even BEFORE FDA Decision . Now is the perfect time to load up before the news about NDA resubmission hit the wire which likely will attract more new investors .GL Evoke Pharma (EVOK) Market-Cap: $21 Million Cash: $6.5 Million Price: $0.87 Shares Out: 24.1 Million Presentation https://evokepharmainc.gcs-web.com/static-files/0f21016a-d472-4005-a293-dd8d02a857e7 •Gimoti™: Novel nasal delivery of metoclopramide for the symptomatic relief of acute and recurrent diabetic gastroparesis in women •Large market opportunity:~12-16M patients with symptoms (80% women); ~2-3M currently treated in US given limited efficacy from few available treatment options •Only one FDA-approved therapy for gastroparesis: Metoclopramide (oral & IV) still has ~4M prescriptions of the oral medication prescribed annually •Positive data from pivotal comparative exposure PK study: Gimoti demonstrated AUC equivalence •Estimated $3-4B prescription market •Resubmission of 505(b)(2) NDA expected Q4 2019 If approved, Gimoti would be the first non-oral pharmacotherapy for gastroparesis approved in 40 years; metoclopramide is currently available in oral and injectable formulations. Evoke Pharma Signs Commercial and Financial Agreement for its Lead Product Gimoti™ in the U.S. with Novos Growth Partners https://www.globenewswire.com/news-...ti-in-the-U-S-with-Novos-Growth-Partners.html Größten Aktionäre Latterell ...2.1M Michigan ...400.0K Garner (Cam L) ...335.6K Gonyer (David A) ...319.5K D’Onofrio ...238.8K The Vanguard ...224.8K Geode Capital ...107.4K Creative ...100.0K Virtu Americas LLC ...70.3K Citadel LLC ...59.0K
NDA filing expected within 2-3 weeks this would boost the stock even higher ..still brutally underpriced at $26 million valuation .GL
